Sarepta Therapeutics Inc

Yesterday, Sarepta Therapeutics received a response from the FDA that raised concerns about its golodirsen new drug application.

Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.

Wall Street analysts expect a potential upside of 77.04% for Sarepta Therapeutics (SRPT) based on the company’s closing price on March 27.

Amarin is expected to dedicate a much higher percentage of its total sales to SG&A but a lower percentage of its total sales to R&D activities as compared to Sarepta Therapeutics from fiscal 2019 to fiscal 2021.

Wall Street analysts have projected Sarepta Therapeutics’ revenues to be $395.55 million, $611.37 million, and $1101.00 million, for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.

In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.

On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.

Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.

In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.

BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.

Sarepta Therapeutics’ revenues are forecast to be $302.13 million in 2018 and $430.37 million in 2019, up from $154.58 million in 2017.

After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy.

On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.

On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.

Sarepta Therapeutics (SRPT) has returned 169.97% YTD. In the second quarter, its EPS was -$0.43, surpassing the consensus estimate by $0.46.

In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.

Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter compared to a net loss of $63.05 million in Q2 2017.

For fiscal 2018 and fiscal 2019, Sarepta is expected to generate revenues of $302.25 million and $428.48 million, respectively.

In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.

On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.

Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.

Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.

Ionis reported 5% YoY growth in revenues to $117.7 million during Q2 2018 as compared to $112.3 million during the second quarter of 2017.

Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.

Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.

Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.

The starting lineup for the Nasdaq All-Stars features names such as MongoDB (NASDAQ: MDB), Etsy Inc. (NASDAQ: ETSY), and Netflix Inc. (NASDAQ: NFLX).

Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.

On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7.

On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.

On June 27, Summit Therapeutics announced that its phase two PhaseOut DMD trial failed to meet its primary endpoint.

In June, PolarityTE stock has been given a “buy” rating by the one analyst covering it. The target price for the stock is $65.

By applying its proprietary platform technologies, Sarepta Therapeutics (SRPT) is able to target a range of diseases and disorders.

On June 19, Sarepta Therapeutics (SRPT) announced positive preliminary results from its phase one part 2a gene therapy micro dystrophin trial.

Versartis (VSAR) stock rose 48.3% in the week of June 1–8. On June 8, it closed at $2.15.

Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating.

In 4Q17, BioMarin Pharmaceutical (BMRN) generated revenue of $358.3 million, compared with $300.1 million in 4Q16.

On March 29, 2018, Spark Therapeutics was trading at $66.59, which represented a ~62% increase from its 52-week low of $41.06.

On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.

On November 16, 2017, the FDA’s Antimicrobial Drugs Advisory Committee voted down the 14-day regimen and 28-day regimen of Nektar Therapeutics’ ciprofloxacin DPI.

European market approval On December 20, 2016, Sarepta Therapeutics (SRPT) announced that the MAA (marketing authorization application) for Exondys 51 (eteplirsen) for Duchenne muscular dystrophy (or DMD) patients above four years of age with mutations amenable to exon-51 skipping was accepted by the EC (European Commission). After receiving initial feedback from the EC related to […]

Demand trends Sarepta Therapeutics (SRPT) reported that by the end of 3Q17, all Tier 1 and Tier 2 sites, which will be treating around 75% of DMD (Duchenne muscular dystrophy) patients with mutations amenable to exon-51 skipping, had submitted start forms for Exondys 51 (eteplirsen). The company has also witnessed an increase in start forms submitted […]

On May 23, the Dow Jones Industrial Average remained unchanged while the SPDR S&P 500 ETF (SPY) went down by 0.1%. The SPDR S&P 500 ETF rose by 0.75 YTD.

For the week ending May 6, the iShares US Medical Devices (IHI) outperformed markets and other biotech ETFs with a return of 0.1%.

The iShares NASDAQ Biotechnology ETF followed the market trend and gained 1.1% after a five-day losing streak, a positive beginning for the month of May.

The SPDR S&P Biotech ETF (XBI) witnessed the best trading day year-to-date in terms of gains on April 6, 2016.

IBB’s top performers for March 21, 2016, were Cara Therapeutics (CARA), OvaScience (OVAS), Sarepta Therapeutics (SRPT), and Aratana Therapeutics (PETX).

The recent fall in BioMarin’s stock price is due to the rejection of its drug Kyndrisa, indicated for Duchenne muscular dystrophy.

The biotechnology industry operates in a dynamic environment embedded with a high-risk business model. The principal risk faced by the industry is R&D failure.

There are four drugs in the pipeline targeting Duchenne muscular dystrophy. The company holds Kyndrisa, BMN044, BMN045, and BMN053 for the indication of DMD.

Here we present an overview of BioMarin. It’s based in California and was founded in 1997. It focuses on therapies for life-threatening rare genetic diseases.

Chimerix closed at $6.62, and its market-cap fell from $1.6 billion to $305 million on December 28, 2015.

The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.

Markets rose in the week ended November 20, as many believed the FED will hike the interest rate in December. The iShares Nasdaq Biotechnology ETF (IBB) rose 3.1%.

Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.

Grifols (GRFS) only fell by 0.34%. It bucked the trend. There were talks that Moody’s upgraded the ratings from “negative” to “stable.”